US 11,890,326 B2
Controlled-release PTH compound
Kennett Sprogøe, Holte (DK); Felix Cleemann, Mainz (DE); Guillaume Maitro, Mannheim (DE); Mathias Krusch, Hirschhorn (DE); Thomas Wegge, Heidelberg (DE); and Joachim Zettler, Heidelberg (DE)
Assigned to ASCENDIS PHARMA BONE DISEASES A/S, Hellerup (DK)
Filed by ASCENDIS PHARMA BONE DISEASES A/S, Hellerup (DK)
Filed on Dec. 8, 2022, as Appl. No. 18/063,294.
Application 18/063,294 is a continuation of application No. 16/337,713, granted, now 11,590,207, previously published as PCT/EP2017/074592, filed on Sep. 28, 2017.
Claims priority of application No. 16191451 (EP), filed on Sep. 29, 2016; and application No. 17155843 (EP), filed on Feb. 13, 2017.
Prior Publication US 2023/0248836 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/29 (2006.01); A61K 47/60 (2017.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 47/54 (2017.01); A61K 47/34 (2017.01)
CPC A61K 38/29 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1647 (2013.01); A61K 47/54 (2017.08); A61K 47/545 (2017.08); A61K 47/60 (2017.08); A61K 47/34 (2013.01)] 11 Claims
 
1. A parathyroid hormone (PTH) conjugate of formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
the unmarked dashed line indicates the attachment by an amide bond to the N-terminal nitrogen of a PTH moiety, the amino acid sequence of which consists of the sequence of SEQ ID NO:51; and the dashed line marked with the asterisk indicates attachment to a moiety

OG Complex Work Unit Chemistry
wherein
m and p are independently an integer ranging from and including 400 to 500.